血清血管内皮生长因子水平作为晚期食管鳞状细胞癌患者根治性食管切除术后化疗或同步放疗后复发的预测指标。

Serum VEGF levels as a predictor of recurrence in patients with advanced‑stage esophageal squamous cell carcinoma following curative esophagectomy followed by chemotherapy or concurrent radiotherapy.

作者信息

Xu Heng, Cao Haixia, Zhang Junying, Jing Changwen, Wang Zhuo, Wu Jianzhong, Du Mengjie, Xu Xuyun, Ma Rong

机构信息

Jiangsu Provincial Institute of Materia Medica, Nanjing Tech University, Nanjing, Jiangsu 210000, P.R. China.

Research Center for Clinical Oncology, Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research and Nanjing Medical University Affiliated Cancer Hospital, Nanjing, Jiangsu 210000, P.R. China.

出版信息

Mol Clin Oncol. 2023 Sep 15;19(5):86. doi: 10.3892/mco.2023.2682. eCollection 2023 Nov.

DOI:10.3892/mco.2023.2682

PMID:37809347

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10557093/

Abstract

The present study evaluated serum levels of vascular endothelial growth factor (VEGF) as a predictor of recurrence in patients with advanced-stage esophageal squamous cell carcinoma (ESCC) following curative esophagectomy followed by chemotherapy or concurrent radiotherapy. Patients with locally advanced resectable ESCC underwent R0 esophagectomy followed by chemotherapy or concurrent radiotherapy as an adjuvant. Serum VEGF levels in 173 patients, including 57 patients with recurrent disease, and 183 healthy controls were determined using a Luminex assay. The results demonstrated that the serum VEGF levels were significantly higher in 57 patients with locally advanced resectable ESCC at recurrence compared with the levels at pre-treatment (P<0.001). The patients with recurrence exhibited significantly higher serum VEGF levels during chemotherapy or concurrent radiotherapy than patients with no recurrence (P<0.05). Patients with low serum VEGF levels had a significantly longer survival time than those with high serum VEGF levels prior to treatment (P<0.01). The median survival times were 70 and 25 months in patients with locally advanced resectable ESCC with serum VEGF levels <161.75 and ≥161.75 pg/ml following treatment, respectively (P<0.01). Compared with patients with VEGF levels <147 pg/ml following treatment, patients with locally advanced resectable ESCC with VEGF levels ≥147 pg/ml had a significantly higher risk of recurrence (P<0.01). Patients with low serum VEGF levels (<147 pg/ml) had significantly higher recurrence-free survival rates than those with high serum VEGF levels (≥147 pg/ml) following treatment (P<0.01). The findings of the present study demonstrate that serum VEGF levels are a potential predictor of recurrence and of the treatment outcomes of chemotherapy or concurrent radiotherapy in patients with locally advanced resectable ESCC.

摘要

本研究评估了血管内皮生长因子（VEGF）血清水平，作为晚期食管鳞状细胞癌（ESCC）患者在根治性食管切除术后接受化疗或同步放疗后复发的预测指标。局部晚期可切除的ESCC患者接受了R0食管切除术，随后进行化疗或同步放疗作为辅助治疗。使用Luminex检测法测定了173例患者（包括57例复发患者）和183例健康对照者的血清VEGF水平。结果表明，57例局部晚期可切除的ESCC复发患者的血清VEGF水平显著高于治疗前水平（P<0.001）。复发患者在化疗或同步放疗期间的血清VEGF水平显著高于未复发患者（P<0.05）。血清VEGF水平低的患者治疗前的生存时间显著长于血清VEGF水平高的患者（P<0.01）。治疗后血清VEGF水平<161.75和≥161.75 pg/ml的局部晚期可切除ESCC患者的中位生存时间分别为70个月和25个月（P<0.01）。与治疗后VEGF水平<147 pg/ml的患者相比，局部晚期可切除的ESCC患者VEGF水平≥147 pg/ml时复发风险显著更高（P<0.01）。治疗后血清VEGF水平低（<147 pg/ml）的患者无复发生存率显著高于血清VEGF水平高（≥147 pg/ml）的患者（P<0.01）。本研究结果表明，血清VEGF水平是局部晚期可切除ESCC患者复发及化疗或同步放疗治疗结果的潜在预测指标。